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ABSTRACT 
Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), a variant of 
pancreatic ductal adenocarcinoma (PDAC), has striking genetic similarity to PDAC 
but a significantly improved overall survival. We hypothesize that this difference 
could be due to the immune response to the tumor, and as such, we investigated the 
expression of PD-1, PD-L1 and CD163 in a series of UCOGC.  
To this aim, 27 pancreatic UCOGCs (11 pure and 16 PDAC-associated), 5 extra-
pancreatic tumors with osteoclast-like giant cells and 10 pancreatic anaplastic 
carcinomas (ACs) were immunostained using antibodies against PD-1, PD-L1 and 
CD163. 
In pancreatic UCOGCs, PD-L1 was expressed in neoplastic cells of 17/27 (63%) 
cases, more often in cases with an associated PDAC (p=0.04). Expression of PD-L1 
was associated with poor prognosis, confirmed by multivariate analysis: patients with 
PD-L1-positive UCOGCs had a risk of all-cause mortality that was 3 times higher 
than patients with PD-L1-negative UCOGCs (HR: 3.397, 95%CI: 1.023-18.375, 
p=0.034). PD-L1 expression on tumor cells was also associated with aberrant P53 
expression (p=0.035). PD-1 was expressed on rare lymphocytes in 12 UCOGCs 
(44.4%), mainly located at the tumor periphery. CD163 was expressed on histiocytes, 
with a diffuse and strong staining pattern in all UCOGCs. Extra-pancreatic tumors 
with osteoclast-like giant cells showed very similar staining patterns for the same 
proteins. ACs have some similarities to UCOGCs, but PD-L1 has no prognostic roles.  
Our results may have important implications for immunotherapeutic strategies in 
UCOGCs; these tumors may also represent a model for future therapeutic approaches 
against PDAC. 
 
KEYWORDS 
UCOGC; PDAC; Osteoclast; Pancreatic cancer; Tumor-associated macrophages. 
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INTRODUCTION 
Pancreatic cancer is a lethal malignancy, and its incidence is still increasing 
[1-4]. The most common subtype of pancreatic cancer is pancreatic ductal 
adenocarcinoma (PDAC) [2-4], which has common somatic mutations in four critical 
driver genes: the oncogene KRAS and the tumor suppressors TP53, CDKN2A and 
SMAD4 [2-6]. There are also several PDAC variants with unique clinical and 
pathological features [2-4]. One of these variants, undifferentiated carcinoma of the 
pancreas with osteoclast-like giant cells (UCOGC), has been recently studied by our 
group with whole-exome sequencing [7]. Intriguingly, despite its unique 
morphological and clinical features, UCOGC had a molecular landscape very similar 
to PDAC. Thus, somatic mutations are unlikely to explain the unique phenotype of 
UCOGC, characterized by undifferentiated and/or anaplastic malignant cells 
intermingled with non-neoplastic histiocytes and osteoclast-like giant cells. In 
addition, differences in somatic mutations are unlikely to explain the unique clinical 
course of UCOGC, with prolonged survival particularly in cases of “pure” UCOGC 
(i.e. not PDAC-associated) [7,8]. 
Recent studies of PDAC suggest that evasion of immune system is a crucial 
step in pancreatic tumorigenesis, with the identification of a significant number of 
immune inhibitory pathways [9-12]. Two of the most promising inhibitory markers 
are programmed death-1 (PD-1), which is expressed on some types of lymphocytes to 
suppress anti-cancer immunity, and its ligand (PD-L1), which is overexpressed in 
most solid malignancies – previous studies have demonstrated that expression of these 
markers has prognostic value in some tumor types [10-12]. Tumor-associated 
macrophages (TAMs) are also a critical component of the tumor immune 
microenvironment. Two classes of TAMs have been identified. The first is the so-
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called TAM1: it expresses IL-1 and IL-6 and, exhibiting a pro-inflammatory 
phenotype, is thought to inhibit tumor development and extension. The second is 
TAM2, which expresses the marker CD163 and supports tumor growth [13,14]. 
TAM2 appears as the most important class of macrophages in pancreatic cancer, 
being involved in many more cases than TAM1 and with also a prognostic 
significance [13-15]. 
Since somatic mutations cannot explain the unique morphology and clinical 
course of UCOGCs, it is possible that such differences are mediated at least in part by 
the tumor immune microenvironment. To address this hypothesis, we investigated the 
expression of PD-1, PD-L1, and CD163 in a series of pancreatic UCOGCs, as well as 
additional cases of tumors with osteoclast-like giant cells from other organs. As 
further control, we also tested a series of anaplastic carcinomas of the pancreas (ACs), 
without osteoclast-like giant cells. 
 
MATERIALS AND METHODS 
The cohort of UCOGCs utilized in this study included cases previously 
analyzed by whole exome sequencing [7], retrieved from the archives of pathology of 
Verona University and Hospital Trust and of The Johns Hopkins Hospital. In 
addition, we collected cases of ACs, of surgically resected pancreatic UCOGCs and 
also of extra-pancreatic neoplasms with osteoclast-like giant cells of other organs 
(UNOGCs) from the previously indicated Institutions and also from Beaujon Hospital 
(Clichy, France), Santa Chiara Hospital (Trento, Italy) and the archives of the 
Department of Pathology and Laboratory Medicine of Indiana University School of 
Medicine (Indianapolis, IN, USA). This study was approved by the Institutional 
Review Boards of all the involved institutions. 
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The immunohistochemical analysis (IHC) was performed using a peroxidase-
based detection system, as already described [16-19], using 4 μm-thick whole sections 
from formalin-fixed paraffin-embedded (FFPE) tissues. The following antibodies for 
PD-1 (source: ABCAM, clone: NAT105, incubation pH=9, dilution 1:100), PD-L1 
(source: Cell Signaling, clone: E1L3N, incubation pH=8, dilution 1:500) and CD163 
(source: Novocastra, clone: 10D, incubation pH=8, dilution 1:200) have been used, 
according to the manufacturer’s instructions. 
PD-1 expression was analyzed in all the types of cells which potentially could 
express this marker, and as previously reported [20] with particular attention to 
lymphocytes. We consider IHC as positive only in case of membranous staining. PD-
L1 expression was evaluated in neoplastic cells of UCOGCs, UNOGCs, ACs and also 
of the differentiated epithelial component when present. It was defined as positive in 
the presence of ≥ 5% of neoplastic cells with membranous staining, as previously 
described [19,21]. The percentage of neoplastic cells positive for PD-L1 was also 
reported. PD-L1 was also evaluated on tumor-associated lymphocytes. CD163 was 
evaluated on histiocytes and osteoclast-like giant cells, and considered as positive 
only in case of membranous staining [22]. The interpretation of the IHC patterns has 
been performed in blind by two gastrointestinal pathologists (C.L., M.F.); any 
inconsistences were resolved by consensus at multi-headed microscope with a third 
pathologist (A.N.). The evaluation of the expression of the biomarkers on 
inflammatory cells (PD-1, PD-L1 on lymphocytes, and CD163) was performed using 
a semi-quantitative (0-5) scoring system: 0 = negative (no positive cells), 1 = rare (1-
10 positive cells per HPF – high power field, 400X), 2 = low (11-20 positive cells per 
HPF), 3 = moderate (21-30 positive cells per HPF), 4 = high (31-50 positive cells per 
HPF), 5 = very high(>50 positive cells per HPF), as reported elsewhere [23].  All the 
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results have been also checked for any possible associations with sequencing data, 
performing ad-hoc statistical analyses in every case of potential association. 
For continuous variables, normal distributions were tested using the 
Kolmogorov-Smirnov test. The data are reported as means and standard deviations 
(SD) for quantitative measures, and frequency and percentages for all discrete 
variables. P-values were calculated for continuous variables using the independent 
Student T-test and for categorical parameters the Fisher’s exact test.  Univariate and 
multivariate (adjusted for age, sex, and presence of PDAC) Cox’s regression models 
were conducted using as exposure the PD-L1 and as outcome overall mortality. The 
results are also reported graphically through Kaplan-Meier curves. All analyses were 
performed using the SPSS 21.0 for Windows (SPSS Inc., Chicago, Illinois). All 
statistical tests were two-tailed and statistical significance was assumed for a p-value 
<0.05. 
 
RESULTS 
The results have been summarized in Table 1 (pancreatic UCOGCs), Table 2 
(UNOGCs), Table 3 (ACs) and in Figure 1. In total, we collected 27 cases of 
pancreatic UCOGCs, 5 UNOGCs from other organs, including 1 bladder carcinoma, 1 
breast carcinoma, and 3 leiomyosarcomas, and 10 ACs.  
Pancreatic UCOGCs 
For the 27 pancreatic cases, we identified expression of PD-L1 in neoplastic 
cells in 17 cases (63%). PD-L1 was expressed more often in PDAC-associated 
UCOGCs (13 PD-L1 positive cases out of 16 PDAC-associated UCOGC, 81.2%, 
expression by both components) compared to “pure” UCOGCs (4/11 cases, 36.3%); 
this difference was statistically significant (Fisher’s exact test, p=0.040). There were 
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no associations with other variables. Furthermore, the tumor infiltrating lymphocytes 
and other inflammatory cells within UCOGCs did not express PD-L1. At the same 
time, there were 7 cases with PD-L1-positive lymphocytes at the periphery of the 
tumor. Among these, 6 were PDAC-associated UCOGCs and 1 was a pure UCOGC, 
with a non-significant trend of increased prevalence of PD-L1-positive lymphocytes 
in PDAC-associated UCOGCs (Fisher’s exact test, p=0.182). In all these 7 cases, the 
expression was low (11 to 20 PD-L1 positive lymphocytes per HPF). All 7 cases with 
PD-L1-positive lymphocytes also had PD-L1 expression in tumor cells. 
There were no tumor infiltrating lymphocytes or other inflammatory cells that 
expressed PD-1 in UCOGCs, except for 2 cases in which there were only rare PD-1-
positive lymphocytes within the tumor (1-10 per HPF). 15 out of 27 UCOGCs 
(55.6%) had no PD-1-positive lymphocytes by IHC. In the remaining 12 cases 
(44.4%), there was a low peri-tumoral infiltrate containing PD-1-positive 
lymphocytes around the UCOGC (11-20 PD-1 positive lymphocytes per HPF). In 
PDAC associated-UCOGCs, PD-1-positive  peri-tumor lymphocytes were present in 
11/16 cases (68.7%), again with a low number of PD-1 positive lymphocytes. In 7 
cases, there were PD-1 lymphocytes only in the PDAC component (Table 1). 
Immunolabeling for CD163 was seen only in histiocytes. Osteoclast-like giant 
cells did not show CD163 expression. In all the pancreatic UCOGCs, there was a 
diffuse and strong staining pattern for CD163 in intratumoral histiocytes, with a very 
high expression of CD163-positive histiocytes (> 50 histiocytes per HPF). CD163-
positive histiocytes were present also in PDAC-associated UCOGCs; in these cases, 
however, the number of such histiocytes was the same in the undifferentiated part but 
lower (moderate expression) in the associated PDAC (21 to 30 CD163 positive 
histiocytes per HPF). 
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The only marker that showed an association with overall survival in our study 
was PD-L1. In univariate analysis, patients with PD-L1-positive UCOGC had a risk 
of all-cause mortality that was more than 4-times that of PD-L1-negative UCOGC 
(HR: 4.256, 95%CI: 1.845-21.454, p=0.022). In multivariate analysis adjusted for 
age, sex, and presence of PDAC, PD-L1 retained a statistically significant value (HR: 
3.397, 95%CI: 1.023-18.375, p=0.034). This prognostic difference is also shown with 
Kaplan-Meier curve (Figure 2). In this cohort, the multivariate analysis on the 
prognostic role of the presence of an associated PDAC did show a higher HR than 
PD-L1 expression, but without reaching a statistical significance (HR: 3.982, 95%CI: 
0.697-22.738, p=0.120). 
There was only one statistically significant association derived from the 
comparison of the expression of PD-L1, PD-1, and CD163 with the molecular data 
from our previous molecular analysis study of UCOGCs [7]. We identified a 
significant association between PD-L1 expression on tumor cells and TP53 
mutational status / P53 expression. From the previous molecular analyses, we 
determined the mutational status of TP53 of 6 cases and the expression pattern of P53 
of 16 cases in the current cohort. All the 5 TP53-mutant cases were PD-L1 positive 
(5/5), and the 1 TP53-wildtype case was PD-L1 negative (0/1) (Fisher’s exact test: 
p=0.16). At the same time, among the 16 cases with known P53 expression (for 6 
cases we have both sequencing and IHC data), 13 had an aberrant P53 expression and 
3 had a normal P53 expression. Among the 13 cases with aberrant P53 expression, 10 
were PD-L1 positive (10/13, 77%), and among the 3 cases with normal P53 
expression, there were no cases with PD-L1 expression (0/3, 0%). The increased 
prevalence of PD-L1 expression in UCOGCs with aberrant P53 expression was 
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statistically significant (Fisher’s exact test, p=0.035). No other associations were 
present among the molecular data and PD-L1, PD-1, or CD163 expression patterns. 
UNOGCs 
One case of bladder cancer with osteoclast-like giant cells and two cases of 
leiomyosarcoma with osteoclast-like giant cells expressed PD-L1 in the neoplastic 
cells. The tumor with the highest percentage of PD-L1-expressing neoplastic cells 
(50%) was a bladder carcinoma. Two tumors had PD-L1 positive lymphocytes: one 
bladder carcinoma and one of three leiomyosarcomas with osteoclast-like giant cells 
(Table 2). The number of PD-L1-positive lymphocytes was in the same range 
observed for pancreatic cases. In addition, there was a moderate intra- and peri-tumor 
infiltrate with PD-1-positive lymphocytes in 4/5 cases. In these 4 cases, there was a 
low infiltrate of PD-1-positive lymphocytes (11-20 per HPF). Finally, in all the 
histiocytes of the 5 non-pancreatic cases, there was a diffuse and strong expression of 
CD163, with the same very high expression pattern observed in pancreatic UCOGCs. 
Pancreatic ACs 
Anaplastic tumors displayed expression of PD-L1 on neoplastic cells in 6 cases 
(60%); differently from UCOGCs, such biomarkers did not play a prognostic role in 
ACs. There were also 4 ACs with PD-L1-positive lymphocytes.  PD-1 was expressed 
on lymphocytes in 7 cases (70%): these PD-1-positive lymphocytes were located not 
only at the periphery of the tumor, as usually in UCOGC, but also inside the lesions 
(so called: “tumor-infiltrating lymphocytes”). CD163 was expressed in all TAMs, but 
they were less than those observed in UCOGCs [(8 ACs with a score of 2 (low: 11-20 
positive cells per HPF) and 2 ACs with a score of 3 (moderate: 21-30 positive cells 
per HPF) vs. 27 UCOGCs, all with a score of 5 (very high, >50 positive cells per 
HPF)]. 
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DISCUSSION 
In this study we present the results of immunohistochemical analysis of 
immunotherapy targets PD-1, PD-L1 and CD163 in case series of 27 pancreatic 
UCOGCs, 5 UNOGCs and 10 ACs. For UCOGC, we found that PD-L1 was 
expressed by the neoplastic cells in the majority of the cases (63%), particularly if 
there was an associated PDAC (p=0.040). Furthermore, this marker predicted a poor 
prognosis in both univariate and multivariate analyses. PD-L1 expression on tumor 
cells was also associated with aberrant P53 expression (p=0.035). Lastly, PD-L1 
expression on lymphocytes was present in 7 cases, but it did not show any statistical 
significant associations. PD-1 was expressed in 44.4% of the cases, and it was present 
on lymphocytes at the periphery of UCOGC and/or of the associated PDAC. Because 
of the lack of intratumor lymphocytes, there was no significant PD-1 expression with 
the UCOGCs (there were only two cases with very rare intra-tumor PD-1 positive 
lymphocytes). Lastly, CD163 showed strong and diffuse expression on histiocytes in 
all UCOGCs. The expression patterns of these biomarkers were also similar for 
UNOGCs and ACs. In the latter, the main differences were the lack of a prognostic 
significance of PD-L1 expression, and the presence of intra-tumor PD-1-positive 
lymphocytes. Our results indicate that the neoplastic cells and associated 
inflammatory cells in UCOGCs, in UNOGCs and in ACs express the analyzed 
biomarkers in a significant number of cases, and thus these tumor types may be 
considered as a target for immunotherapy. Notably, PD-L1 was prognostically 
significant only in UCOGC. 
There is only one paper in the literature analyzing the expression of PD-L1 in 
undifferentiated carcinoma of the pancreas, showing a higher frequency (63%) of PD-
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L1 expression on neoplastic cells in undifferentiated carcinoma compared with a 
cohort of PDACs (15%); no prognostic correlations emerged on the basis of PD-L1 
expression in this study [24]. In this study, 24 undifferentiated carcinomas were 
analyzed, but only 5 were UCOGCs; 4 out of 5 UCOGCs were PD-L1 positive [24]. 
Our paper investigates a larger series of UCOGCs, and the results on the prevalence 
of PD-L1 expression (65.2% in our series) are in line with this recent report. Also our 
results on ACs (in 60% of cases the neoplastic cells were PD-L1 positive) confirm 
this high prevalence among undifferentiated pancreatic tumors.  
We also found that this marker plays a significant prognostic role in UCOGCs, 
and it is probable that the lack of similar results in the previous report is due to the 
small number of UCOGCs (only 5). Since in our previous study we described an 
association between the presence of an associated PDAC with an increased risk of 
death, we have investigated the prognostic role of PD-L1 expression and also of the 
presence of an associated PDAC with multivariate analysis in this cohort. Although 
the presence of an associated PDAC presented a reliable but not statistically 
significant trend with a poorer prognosis, PD-L1 expression did show a statistically 
significant association (HR: 3.397, 95%CI: 1.023-18.375, p=0.034). In the previous 
study by Lehrke et al. the expression of PD-L1 on lymphocytes was not analyzed; 
although we analyze such expression in our paper, it appears less biologically and 
prognostically significant compared to the expression on tumor cells. There are also 
relatively few studies in the literature on the expression of PD-L1 in PDAC.  Its 
expression ranges from 30.6% to 63.3% in distinct studies, as highlighted in a recent 
original manuscript with literature review [25]. These differences might be 
attributable to the use of different clones and to the lack of standardized procedures of 
PD-L1 evaluation. In our study, however, we have used a method which has been 
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well-standardized in our laboratory and which has also been used during routine 
practice. Notably, as in our study, all these previous papers confirm the negative 
prognostic role of PD-L1 in pancreatic carcinoma. Indeed, in PDAC Imai and 
colleagues showed a strong correlation between the lack of expression of PD-L1 and a 
better prognosis [25]. Similarly, Tessier-Cloutier et al. showed an inverse relationship 
between PD-L1 expression and disease-free survival [26], and Wang et al. described 
that high expression of PD-L1 on cancer cell membranes correlated with nodal 
metastasis and with poor differentiation [27]. Conversely, although PD-L1 was 
expressed in the majority of ACs in our study, this biomarker did not play a 
prognostic role in this tumor type. This result is in line with the paper by Lehrke et al. 
[24] and may be due to the very poor prognosis of ACs and also to the different 
immunologic microenvironment between UCOGCs and ACs (e.g.: absence of 
osteoclast-like giant cells and presence of intra-tumor lymphocytes in ACs). It is also 
true that the small sample size of our study and of the cohort of Lehrke et al. cannot 
permit definitive conclusions in this sense. 
Noticeably, there are several therapeutics currently in use for the treatment of 
solid tumors expressing PD-L1, inhibiting the immune-checkpoint PD-1/PD-L1. The 
decision on whether to use such therapeutics is typically based on an IHC test for PD-
1/PD-L1, though different antibody clones and different thresholds are used for 
different therapeutics and different tumor types. Despite of the lack of standardized 
regimens, on the basis of their expression patterns, UCOGCs and ACs may represent 
another tumor type in which these PD-1/PD-L1 targeting therapeutic strategies should 
be tested. Recent studies have also highlighted the possible utility of PD-L1 directed 
therapy in tumors with altered DNA mismatch repair status [24,28].  
Intriguingly, we also identified an association between the expression of PD-
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L1 on tumor cells and aberrant P53 expression. This association has been already 
described using cell lines and also in non-small cell lung cancer [29] but never for 
pancreatic cancer, and points out the intimate correlation of PD-L1 with tumor 
biology. This association may be also of importance in influencing the poorer 
prognosis of PD-L1 positive cases, since such tumors exhibit a more aggressive 
biological behavior [29,30]. 
To our knowledge there are no previous studies describing expression of PD-1 
in pancreatic undifferentiated carcinoma. In PDAC the expression of PD-1 on the 
lymphocytes has been correlated with a better prognosis [11,31]. In our study we 
demonstrate the presence of PD-1 positive lymphocytes in 12 UCOGCs (44.4%), but 
we did not identify any prognostic correlates for this marker. This may be due to the 
limited role played by such lymphocytes, which are indeed located only at the 
periphery of the tumor. In ACs, PD-1 was expressed on lymphocytes in 70% of cases; 
they were located not only at the periphery of the tumor, but inside the lesions (so 
called: “tumor-infiltrating lymphocytes”). The presence of intra-tumor lymphocytes 
represent a major difference in the expression patterns of the analyzed biomarkers 
between UCOGCs and ACs.  Also of interest is the expression of PD-1 on 
lymphocytes in only the PDAC component in 7 cases of PDAC-associated UCOGCs. 
This finding highlights the heterogeneity of PD-1 expression, indicating a potentially 
more important biological function of such marker in PDAC than in UCOGC. 
CD163, a marker of TAM2 macrophages, has been already indicated as a poor 
prognostic moderator in PDAC [13,14], but in the literature no data exist about its 
expression in UCOGCs. This type of cancer is very rich in macrophages, and we 
show that these macrophages are TAM2. In ACs there are also this type of 
histiocytes, but they are less than those we described in UCOGCs, highlighting that 
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TAM2 are more specifically related to UCOGC microenvironment. Also through the 
secretion of immunosuppressive cytokines, TAM2 promote proliferation and survival 
of tumor cells, angiogenesis, matrix remodeling and metastasis [13,14,31,32]. In 
UCOGCs, we show that neoplastic cells and osteoclast-giant cells are surrounded by a 
dense net of TAM2 macrophages, thus this tumor type may be investigated as a 
potential model for testing therapies blocking TAM2 or that aim at converting TAM2 
in TAM1  [13,33,34]. 
The study of these markers on extra-pancreatic cases have also highlighted 
that there are biological similarities between UNOGCs and UCOGCs, not only for the 
presence of osteoclast-like giant cells, but also in terms of immunological 
microenvironment. This confirmed that such biomarkers might have a certain 
importance in tumors with osteoclast-like giant cells of different districts, but further 
studies with larger series are needed to confirm these findings. 
Our study does have some limitations. First, we have used only a single clone 
for each antibody, but for PD-1/PD-L1 there are at least four different diagnostic 
immunohistochemical assays, applicable for the different available therapeutics. This 
complicates the uniformity and the reproducibility of the interpretation of IHC 
analysis; however, we have used antibodies well-standardized in our laboratory and 
also used for routine practice. Furthermore, we have not included other 
immunohistochemical markers, potentially useful to further characterize the immune 
cells in UCOGCs, but we have focused our attention on the most important 
biomarkers for immunotherapy. Unfortunately, due to use of material for previous 
molecular analyses, our tissue for IHC assays was limited. For this reason we focused 
on markers relevant to existing immunotherapy approaches to maximize the clinical 
impact of our study. Finally, our cohort of extrapancreatic cases and ACs are very 
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small and without clinical follow-up for UNOGCs. Still, we include these cases as an 
exploratory cohort to explore the main similarities and differences among UCOGCs, 
UNOGCs and ACs; these findings should be confirmed in larger cohorts of cases, but 
our study has indicated potential perspectives for future researches. 
In conclusion, the most important results of our study regard the expression of 
PD-L1, PD-1, and CD163 in UCOGCs, specifically demonstrating prognostic 
significance of PD-L1 expression in neoplastic cells. UCOGC is a rare subtype of 
pancreatic cancer, but the specific patterns of expression of such markers suggest that 
this tumor type should be considered as a potential target for immunotherapy. In 
particular, UCOGCs with associated PDAC and/or with mutations of TP53 should be 
assayed for PD-L1 expression, as these UCOGCs had the highest prevalence of PD-
L1 expression in our cohort. 
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FIGURES LEGEND 
Figure 1. Immunohistochemical staining pattern in representative cases. A: in this 
case there are some clusters of neoplastic cells that are PD-L1 positive; note 
osteoclast-like giant cells (arrow) that are totally negative (original magnification: 
10X). B: in this cases there are some peri-tumor PD-1 positive lymphocytes; there are 
not intra-tumor lymphocytes (original magnification: 10X). C: the wide and diffuse 
net of positivity of CD163-positive histiocytes is here shown (original magnification: 
2X). D: the staining pattern of CD163 at higher magnification: note the osteoclast-like 
giant cells (arrow) and the neoplastic cells that are totally negative (original 
magnification: 10X). 
 
Figure 2. Kaplan-Meier curve indicates a better survival for PD-L1 negative patients. 
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Table 1. Expression of PD-L1, PD-1 and CD163 in 
undifferentiated carcinoma of the pancreas with osteoclast-
like giant cells (UCOGC) 
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              Abbreviations (in alphabetical order): IT: intra-tumor; LN mets: lymph node metastasis; NA: 
not available; OS: overall survival;  PDAC: pancreatic ductal adenocarcinoma; POS: positive; 
PT: peri-tumor.  For the biomarkers PD-L1, PD-1 and CD163, we reported between squared 
brackets the score indicating their expression [the score ranges from 0 (absence of 
positivity) to 5 (strong and diffuse expression); see the main text]. When there is an 
associated cancer, we reported between brackets the value of UCOGC first, and then the 
value of the associated cancer. 
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Table 2. Expression of PD-L1, PD-1 and CD163 in extrapancreatic 
UNOGC 
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       Abbreviations (in alphabetical order): BC:bladder carcinoma,  BRC: breast cancer and LM: 
leyomyosarcoma, with osteoclast-like giant cells; POS: positive; PT: peri-tumor; UNOCG: 
undifferentiated neoplasm with osteoclast-like giant cells. For the biomarkers, we reported 
between squared brackets the score indicating their expression [the score ranges from 0 
(absence of positivity) to 5 (strong and diffuse expression); see main text]. 
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Table 3. Expression of PD-L1, PD-1 and CD163 in 
anaplastic carcinoma of the pancreas           
             Sa
m
pl
e 
A
g
e 
S
e
x 
Ne
oad
j Tx 
Tumor 
Stage 
(AJCC) 
LN 
me
ts 
Vascul
ar 
Invasi
on 
Perine
ural 
Invasio
n 
OS 
(mo
nths
) 
PD-L1 
tumor 
cells 
PD-L1 
lymph
ocytes PD-1 
CD
16
3 
I 
7
0 M No T2 
Ye
s Yes Yes 
Alive 
(10) 
POS 
[50%] 0 
POS 
[2-
IT,PT
] 
PO
S 
[2] 
II 
7
4 F No T1c No Yes Yes 
Alive 
(4) 0 0 0 
PO
S 
[3] 
III 
7
8 M No T2 
Ye
s Yes Yes 
Dea
d (2) 
POS 
[10%] POS [1] 
POS 
[3-
IT,PT
] 
PO
S 
[3] 
IV 
6
6 F No T2 
Ye
s Yes Yes 
Dea
d 
(11) 
POS 
[30%] POS [1] 
POS 
[2-
IT,PT
] 
PO
S 
[2] 
V 
6
1 M No T3 
Ye
s Yes Yes 
Dea
d (8) 
POS 
[40%] POS [1] 
POS 
[1-
IT,PT
] 
PO
S 
[2] 
VI 
5
4 M No T2 
Ye
s Yes Yes NA 0 0 0 
PO
S 
[2] 
VII 
6
1 F No T1b 
Ye
s* Yes Yes 
Alive 
(120
) 
POS 
[10%] POS [1] 
POS 
[3-
IT,PT
] 
PO
S 
[2] 
VII
I 
6
0 M Yes T3 
Ye
s Yes Yes 
Alive 
(27) 
POS 
[5%] 0 
POS 
[1-
IT,PT
] 
PO
S 
[2] 
IX 
6
8 F No T2 
Ye
s Yes Yes 
Dea
d (2) 0 0 0 
PO
S 
[2] 
X*
* 
8
3 F No T3 
Ye
s Yes Yes 
Dea
d (9) 0 0 
POS 
[1-
IT] 
PO
S 
[2] 
             Notes: * Only one metastatic lymph node, and with the features of the "direct extension" of 
tumor to the lymph node. ** Biopsy material (this patient did not undergo surgical 
resection) 
             Abbreviations (in alphabetical order): IT: intra-tumor; LN mets: lymph node metastasis; OS: 
overall survival; NA: not available; POS: positive; PT: peri-tumor. For the biomarkers PD-L1, 
PD-1 and CD163, we reported between squared brackets the score indicating their 
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expression [the score ranges from 0 (absence of positivity) to 5 (strong and diffuse 
expression); see the main text]. 
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HIGHLIGHTS 
1. UCOGC is a variant of PDAC, genetically very similar.  
2. We investigate the complex immunologic microenvironment of UCOGC. 
3. We look for potential targets for immunotherapy, as PD-L1, PD-1 and CD163. 
4. PD-L1 expression on neoplastic cells of UCOGC demonstrate a poor 
prognostic value. 
5. Other immune-therapuetic targets, as PD-1 and CD163, are also expressed in 
UCOGC. 
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